Clinical Investigation of Plasma Copeptin Level on Major Adverse Cardiovascular Event in Patients With Acute ST-segment Elevation Myocardial Infarction During Hospitalization / 中国循环杂志

ABSTRACT

Objective: To explore the clinical value of plasma copeptin level on major adverse cardiovascular event (MACE) occurrence in patients with acute ST-segment elevation myocardial infarction (STEMI) during hospitalization. Methods: Our research included 2 groupsSTEMI group, n=80 and Control group, n=80 patients with stable coronary artery disease (CAD). All patients were treated in our hospital from 2012-06 to 2014-06. Plasma level of copeptin was detected by ELISA, other relevant examinations were conducted to study the MACE occurrence in STEMI patients. Results: Plasma copeptin level in STEMI group (523.26 ± 142.69) pg/ml was higher than that in Control group (345.25 ± 89.36) pg/ml, P Conclusion: Plasma copeptin level could effectively predict MACE occurrence in patients with acute STEMI during hospitalization, it may predict their prognosis at certain point.